col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


80 Results       Page 1

 [1] 
Elsevier: European Journal of Medicinal Chemistry
  original article Date Title Authors   All Authors
1 [GO] 2024―Jul―24 N-Acylbenzimidazoles as Selective Acylators of the Catalytic Cystein of the Coronavirus 3CL Protease. Fatima-Zahra Chaibi, Lucile Brier, Paul Carré, Valérie Landry, Lowiese Desmarets, Audrey Tarricone, et al. (+14)
2 [GO] 2024―Jul―11 Novel compounds with dual inhibition activity against SARS-CoV-2 critical enzymes RdRp and human TMPRSS2 Sameh.S.M. Soliman, Alshaimaa M. Hamoda, Yogendra Nayak, Ahmed Mostafa, Rania Hamdy
3 [GO] 2024―Jun―25 Development of novel antivrial agents that induce the degradation of the main protease of human-infecting coronaviruses Shuihong Cheng, Yong Feng, Wei Li, Tong Liu, Xun Lv, Xiaomei Tong, et al. (+3)
4 [GO] 2024―May―16 Discovery of meisoindigo derivatives as noncovalent and orally available Mpro inhibitors: their therapeutic implications in the treatment of COVID-19 Qingtian Gao, Sixu Liu, Yuzheng Zhou, Jinbao Fan, Shufen Ke, Yuqing Zhou, et al. (+5)
5 [GO] 2024―Apr―25 Medicinal chemistry strategies toward broad-spectrum antiviral agents to prevent next pandemics Zirui Lü, Xiandong Dai, Jianjie Xu, Zhenming Liu, Yongbiao Guo, Zhenhua Gao, Fanhua Meng
6 [GO] 2024―Feb―24 Synthesis and biological evaluation of novel Peptidomimetic inhibitors of the coronavirus 3C-like protease Franck Amblard, Julia C. Le Cher, Ramyani De, Shaoman Zhou, Peng Liu, Shu Ling Goh, et al. (+14)
7 [GO] 2024―Feb―12 Design, synthesis and biological evaluation of novel 1,2,4a,5-tetrahydro-4H-benzo[b][1,4]oxazino[4,3-d][1,4]oxazine-based AAK1 inhibitors with anti-viral property against SARS-CoV-2 Nian-Dong Mao, Yueying Xu, Hao Che, Xia Yao, Yuan Gao, Chenchen Wang, et al. (+4)
8 [GO] 2024―Feb―06 Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity Jenny Desantis, Alessandro Bazzacco, Michela Eleuteri, Sara Tuci, Elisa Bianconi, Antonio Macchiarulo, et al. (+3)
9 [GO] 2024―Feb―01 Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors Arun K. Ghosh, Monika Yadav, Satyanarayana Iddum, Somayeh Ghazi, Emma K. Lendy, Uttara Jayashankar, et al. (+7)
10 [GO] 2024―Jan―09 Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization Tania Ciaglia, Vincenzo Vestuto, Veronica Di Sarno, Simona Musella, Gerardina Smaldone, Francesca Di Matteo, et al. (+15)
11 [GO] 2023―Dec―05 Structure-based design of SARS-CoV-2 papain-like protease inhibitors Prakash Jadhav, Bo Huang, Jerzy Osipiuk, Xiaoming Zhang, Haozhou Tan, Christine Tesar, et al. (+7)
12 [GO] 2023―Nov―30 Plant-derived strategies to fight against severe acute respiratory syndrome coronavirus 2 Wenkang Li, Tianze Ding, Huimin Chang, Yuanchang Peng, Jun Li, Xin Liang, et al. (+4)
13 [GO] 2023―Nov―25 Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection Lei Tian, Taotao Qiang, Xiuding Yang, Yue Gao, Xiaopei Zhai, Kairui Kang, et al. (+6)
14 [GO] 2023―Nov―25 Design, synthesis and biological evaluation of biaryl amide derivatives against SARS-CoV-2 with dual-target mechanism Jiayu Li, Xiuli Zhong, Hongying Li, Zhihui Yu, Jianrui Li, Qionglu Duan, et al. (+7)
15 [GO] 2023―Nov―01 Highly potent dual-targeting angiotensin-converting enzyme 2 (ACE2) and Neuropilin-1 (NRP1) peptides: A promising broad-spectrum therapeutic strategy against SARS-CoV-2 infection Shuang Mei, Yunting Zou, Su Jiang, Lu Xue, Yuting Wang, Han Jing, et al. (+5)
16 [GO] 2023―Oct―31 Targeting SARS-CoV-2 entry processes: The promising potential and future of host-targeted small-molecule inhibitors Aijia Wu, Kunyu Shi, Jiaxing Wang, Ruofei Zhang, Yuxi Wang
17 [GO] 2023―Sep―25 Design, synthesis, and structure-activity relationships of a novel class of quinazoline derivatives as coronavirus inhibitors Shengchao Zhou, Kun Wang, Ziwei Hu, Tao Chen, Yao Dong, Rongmei Gao, et al. (+3)
18 [GO] 2023―Aug―28 Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review Xin Li, Yongcheng Song
19 [GO] 2023―Aug―28 Synthesis of cannabidiol-based compounds as ACE2 inhibitors with potential application in the treatment of COVID-19 Gabriel Vitor de Lima Marques, Daisymara Priscila de Almeida Marques, Felipe Alves Clarindo, Jesus Alberto Avendaño-Villarreal, Fabiana Sélos Guerra, Patrícia Dias Fernandes, et al. (+8)
20 [GO] 2023―Aug―18 Discovery of antiviral SARS-CoV-2 main protease inhibitors by structure-guided hit-to-lead optimization of carmofur Koon Mook Kang, Yejin Jang, Sang Soo Lee, Mi Sun Jin, Chang-Duk Jun, Meehyein Kim, Yong-Chul Kim
21 [GO] 2023―Aug―17 Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19 Fu-Mao Zhang, Ting Huang, Feng Wang, Gui-Shan Zhang, Donglan Liu, Jun Dai, et al. (+6)
22 [GO] 2023―Aug―13 Novel mono- and multivalent N-acetylneuraminic acid glycoclusters as potential broad-spectrum entry inhibitors for influenza and coronavirus infection Xingxing Zhu, Yanliang Yi, Zibo Fan, Ruiwen Liu, Xindang Chu, Mengyang Wang, et al. (+6)
23 [GO] 2023―Aug―10 A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19 Narva Deshwar Kushwaha, Jivanka Mohan, Babita Kushwaha, Terisha Ghazi, Joshua C. Nwabuife, Neil Koorbanally, Anil A. Chuturgoon
24 [GO] 2023―Jul―20 Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease Chong Huang, Rui Zeng, Jingxin Qiao, Baoxue Quan, Ronghua Luo, Qiao Huang, et al. (+12)
25 [GO] 2023―Jul―19 Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors Bin Tan, Michael Sacco, Haozhou Tan, Kan Li, Ryan Joyce, Xiujun Zhang, et al. (+2)
26 [GO] 2023―May―24 Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro) Kuojun Zhang, Tianyu Wang, Maotian Li, Mu Liu, He Tang, Lin Wang, et al. (+7)
27 [GO] 2023―May―23 Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CLpro inhibitors against SARS-CoV-2 Hanxi Yang, Mengyuan You, Xiaoyang Shu, Jingyao Zhen, Mengwei Zhu, Tiantian Fu, et al. (+8)
28 [GO] 2023―May―22 The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022 Xiaojing Pang, Wei Xu, Yang Liu, Hua Li, Lixia Chen
29 [GO] 2023―May―11 Structure-guided optimization of adenosine mimetics as selective and potent inhibitors of coronavirus nsp14 N7-methyltransferases Marcel Hausdorff, Adrien Delpal, Sarah Barelier, Laura Nicollet, Bruno Canard, Franck Touret, et al. (+5)
30 [GO] 2023―Apr―17 Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19 Fatema Hersi, Anusha Sebastian, Hamadeh Tarazi, Vunnam Srinivasulu, Ahmed Mostafa, Abdou Kamal Allayeh, et al. (+8)
31 [GO] 2023―Apr―15 Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV) Chamandi S. Dampalla, Matthew J. Miller, Yunjeong Kim, Alexandria Zabiegala, Harry Nhat Nguyen, Trent K. Madden, et al. (+8)
32 [GO] 2023―Mar―31 Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination Irina Stefanelli, Angela Corona, Carmen Cerchia, Emilia Cassese, Salvatore Improta, Elisa Costanzi, et al. (+11)
33 [GO] 2023―Mar―18 Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2 Mohamed S. Bekheit, Siva S. Panda, Adel S. Girgis
34 [GO] 2023―Mar―13 Repurposing 1,2,4-oxadiazoles as SARS-CoV-2 PLpro inhibitors and investigation of their possible viral entry blockade potential Mohammed Salah Ayoup, Mariam M. ElShafey, Hamida Adbel-hamid, Doaa A. Ghareeb, Marwa M. Abu-Serie, Lamia A. Heikal, Mohamed Teleb
35 [GO] 2023―Feb―28 Korupensamine A, but not its atropisomer, korupensamine B, inhibits SARS-CoV-2 in vitro by targeting its main protease (Mpro) Ahmed M. Sayed, Alyaa Hatem Ibrahim, Nasir Taj�n, Jürgen Seibel, Jochen Bodem, Nina Geiger, et al. (+3)
36 [GO] 2023―Feb―06 Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses Lucile Brier, Haitham Hassan, Xavier Hanoulle, Valerie Landry, Danai Moschidi, Lowiese Desmarets, et al. (+14)
37 [GO] 2023―Jan―28 Development of indolealkylamine derivatives as potential multi-target agents for COVID-19 treatment Jyoti Chauhan, Erika Cecon, Nedjma Labani, Florence Gbahou, Fernando Real, Morgane Bomsel, et al. (+5)
38 [GO] 2023―Jan―18 Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2 Pengxuan Ren, Changyue Yu, Ruxue Zhang, Tianqing Nie, Qiaoyu Hu, Hui Li, et al. (+11)
39 [GO] 2023―Jan―17 Identification of a short ACE2-derived stapled peptide targeting the SARS-CoV-2 spike protein Lorenzo Calugi, Giulia Sautariello, Elena Lenci, Mauro Leucio Mattei, Crescenzo Coppa, Nicoletta Cini, et al. (+2)
40 [GO] 2023―Jan―10 Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses Qifan Zhou, Yinzhu Luo, Yujun Zhu, Qishu Chen, Jingfei Qiu, Feng Cong, et al. (+2)
41 [GO] 2022―Dec―15 Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors Santo Previti, Roberta Ettari, Elsa Calcaterra, Salvatore Di Maro, Stefan J. Hammerschmidt, Christin Müller, et al. (+4)
42 [GO] 2022―Oct―19 Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2 Simone Di Micco, Rahila Rahimova, Marina Sala, Maria C. Scala, Giovanni Vivenzio, Simona Musella, et al. (+10)
43 [GO] 2022―Oct―17 Easy access to α-ketoamides as SARS-CoV-2 and MERS Mpro inhibitors via the PADAM oxidation route Sveva Pelliccia, Carmen Cerchia, Francesca Esposito, Rolando Cannalire, Angela Corona, Elisa Costanzi, et al. (+7)
44 [GO] 2022―Oct―03 Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen Liying Wang, Zhongtian Yu, Shiwei Wang, Zheng Guo, Qi Sun, Luhua Lai
45 [GO] 2022―Jul―11 Discovery of potent Benzoxaborole inhibitors against SARS-CoV-2 main and dengue virus proteases Nikos Kühl, Johannes Lang, Mila M. Leuthold, Christian D. Klein
46 [GO] 2022―Jul―08 A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals Yugendar R. Alugubelli, Zhi Zachary Geng, Kai S. Yang, Namir Shaabani, Kaustav Khatua, R. Ma Xinyu, et al. (+12)
47 [GO] 2022―Jul―03 Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors Mehdi Valipour
48 [GO] 2022―Jun―27 A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals Yuying Ma, Kai S. Yang, Zhi Zachary Geng, Yugendar R. Alugubelli, Namir Shaabani, Erol C. Vatansever, et al. (+12)
49 [GO] 2022―Jun―03 Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease Xiaodong Dou, Qi Sun, Guofeng Xu, Yameng Liu, Caifang Zhang, Bingding Wang, et al. (+12)
50 [GO] 2022―May―13 The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate Hao Wang, Rongjuan Pei, Xin Li, Weilong Deng, Shuai Xing, Yanan Zhang, et al. (+11)
51 [GO] 2022―May―07 Identification, optimization, and biological evaluation of 3-O-β-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein Hui Li, Chen Cheng, Shanshan Shi, Yan Wu, Yongfeng Gao, Zhihao Liu, et al. (+6)
52 [GO] 2022―Mar―19 Design, synthesis and biological evaluation of niclosamide analogs against SARS-CoV-2 Yu-Pu Juang, Yu-Ting Chou, Ru-Xian Lin, Hsiu-Hua Ma, Tai-Ling Chao, Jia-Tsrong Jan, et al. (+2)
53 [GO] 2022―Feb―04 Antioxidant, anti-inflammatory and immunomodulatory roles of vitamins in COVID-19 therapy Aurelia Magdalena Pisoschi, Aneta Pop, Florin Iordache, Loredana Stanca, Ovidiu Ionut Geicu, Liviu Bilteanu, Andreea Iren Serban
54 [GO] 2022―Jan―23 In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease Muya Xiong, Tianqing Nie, Qiang Shao, Minjun Li, Haixia Su, Yechun Xu
55 [GO] 2022―Jan―13 Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition Vanna Sanna, Sandro Satta, Tzung Hsiai, Mario Sechi
56 [GO] 2021―Dec―11 Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors Julia K. Stille, Jevgenijs Tjutrins, Guanyu Wang, Felipe A. Venegas, Christopher Hennecker, Andrés M. Rueda, et al. (+14)
57 [GO] 2021―Dec―01 Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19 Jian-Wei Zhang, Yuan Xiong, Feng Wang, Fu-Mao Zhang, Xiaodi Yang, Guo-Qiang Lin, et al. (+3)
58 [GO] 2021―Nov―01 Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2 Yi-Ting Wang, Xin-Yan Long, Xiao Ding, Shi-Rui Fan, Jie-Yun Cai, Bi-Juan Yang, et al. (+9)
59 [GO] 2021―Oct―05 Screening S protein - ACE2 blockers from natural products: Strategies and advances in the discovery of potential inhibitors of COVID-19 Le-le Ma, Hui-min Liu, Xue-mei Liu, Xiao-yu Yuan, Chao Xu, Fang Wang, et al. (+3)
60 [GO] 2021―Sep―22 Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization Veronica Di Sarno, Gianluigi Lauro, Simona Musella, Tania Ciaglia, Vincenzo Vestuto, Marina Sala, et al. (+13)
61 [GO] 2021―Sep―21 Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus Naglaa Salem El-Sayed, Alexander S. Jureka, Megan R. Edwards, Sandeep Lohan, Caroline G. Williams, Patrick T. Keiser, et al. (+5)
62 [GO] 2021―Aug―18 Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors Jiahua Cui, Jinping Jia
63 [GO] 2021―Jul―05 System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2 Ilaria Vicenti, Maria Grazia Martina, Adele Boccuto, Marta De Angelis, Giorgia Giavarini, Filippo Dragoni, et al. (+10)
64 [GO] 2021―Jun―10 Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors Guo-Ning Zhang, Jianyuan Zhao, Quanjie Li, Minghua Wang, Mei Zhu, Juxian Wang, et al. (+2)
65 [GO] 2021―May―30 Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: structural enhancements, increased solubility, and micellar studies Wayne Vuong, Conrad Fischer, Muhammad Bashir Khan, Marco J. van Belkum, Tess Lamer, Kurtis D. Willoughby, et al. (+10)
66 [GO] 2021―May―05 A Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease Adam G. Kreutzer, Maj Krumberger, Elizabeth M. Diessner, Chelsea Marie T. Parrocha, Michael A. Morris, Gretchen Guaglianone, et al. (+2)
67 [GO] 2021―Mar―20 Structure-Based Drug Design of an Inhibitor of the SARS-CoV-2 (COVID-19) Main Protease Using Free Software: A Tutorial for Students and Scientists Sheng Zhang, Maj Krumberger, Michael A. Morris, Chelsea Marie T. Parrocha, Adam G. Kreutzer, James S. Nowick
68 [GO] 2021―Feb―15 Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors? Sk. Abdul Amin, Suvankar Banerjee, Shovanlal Gayen, Tarun Jha
69 [GO] 2021―Feb―09 Discovery and Structural Optimization of 3-O-β-Chacotriosyl Oleanane-type Triterpenoids as Potent Entry Inhibitors of SARS-CoV-2 Virus Infections Hui Li, Chen Cheng, Sumei Li, Yan Wu, Zhihao Liu, Mingjian Liu, et al. (+5)
70 [GO] 2021―Jan―22 RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic Lei Tian, Taotao Qiang, Chengyuan Liang, Xiaodong Ren, Minyi Jia, Jiayun Zhang, et al. (+6)
71 [GO] 2021―Jan―13 The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2 Irshad Ahmad
72 [GO] 2020―Sep―19 Primed for Global Coronavirus Pandemic: Emerging Research and Clinical Outcome Shakir Ahamad, Scotty Branch, Shea Harrelson, Mohd Kamil Hussain, Mohammad Saquib, Saeed Khan
73 [GO] 2020―Aug―06 The Development of Coronavirus 3C-Like Protease (3CLpro) Inhibitors from 2010 to 2020 Yuzhi Liu, Chengyuan Liang, Liang Xin, Xiaodong Ren, Lei Tian, Xingke Ju, et al. (+9)
74 [GO] 2020―Aug―01 Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds Pei Liu, Hongbo Liu, Qi Sun, Hao Liang, Chunmei Li, Xiaobing Deng, et al. (+2)
75 [GO] 2020―Jul―28 Potential treatment methods targeting 2019-nCoV infection Lu Zheng, Lina Zhang, Jiamin Huang, Kutty Selva Nandakumar, Shuwen Liu, Kui Cheng
76 [GO] 2020―Jul―15 COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus Vladimir V. Kouznetsov
77 [GO] 2020―Jul―15 Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses Canan G. Nebigil, Christiane Moog, Stéphan Vagner, Nadia Benkirane-Jessel, Duncan R. Smith, Laurent Désaubry
78 [GO] 2020―Jun―12 Fight against novel coronavirus: A perspective of medicinal chemists Sk. Abdul Amin, Tarun Jha
79 [GO] 2020―Jun―12 Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase Rostom Ahmed-Belkacem, Priscila Sutto-Ortiz, Mathis Guiraud, Bruno Canard, Jean-Jacques Vasseur, Etienne Decroly, Françoise Debart
80 [GO] 2020―Jun―06 A Promising Antiviral Candidate Drug for the COVID-19 Pandemic: A Mini-Review of Remdesivir Chengyuan Liang, Lei Tian, Yuzhi Liu, Nan Hui, Guaiping Qiao, Han Li, et al. (+5)
 [1] 

80 Results       Page 1


[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec